Amedica announced preliminary 1Q17 revenue of US $2.6MM, -37.7% vs. 1Q16, and 2Q17 revenue of $3.2MM, -20.0% vs. 2Q16, totaling preliminary 1H17 revenue of $5.8MM, -29.0% vs. 1H16.
The majority of the spine market-just about 80%-is controlled by companies with annual spine revenue above $100 million. See a detailed breakdown of the top players.
Bone Therapeutics reports positive interim efficacy results and early conclusion of the Phase I/IIA study of ALLOB® allogeneic bone cell therapy in the treatment of delayed-union fractures.